Why did Drugnews highlight TSY-110’s route to pivotal development?
Drugnews’s October 30, 2026 analysis highlights Formosa Pharmaceuticals and EirGenix’s TSY-110, a Kadcyla biosimilar, because a European clinical trial application was filed on August 28, 2026. The article describes a March 2022 alliance worth up to US$30 million in upfront and milestone payments and a reference-product market of about US$2.5 billion in 2025 Kadcyla sales. Its pivotal-entry ranking is an editorial forecast.
| Measure | Reported result | Basis |
|---|---|---|
| European clinical trial application | August 28, 2026 | Application filing; not trial initiation or approval |
| Alliance consideration | Up to US$30 million | Upfront and milestones; not all money received |
| Kadcyla reference-product sales | About US$2.5 billion | 2025 global sales; not TSY-110 revenue |
| Expected first-patient announcement | By June 30, 2027 | Drugnews editorial forecast, not a company commitment |
Formosa describes TSY-110 as an IND-enabling program with clinical initiation expected. Neither a filing nor the article’s forecast establishes that dosing has begun.